Top Markets
Coin of the day
Eli Lilly Eli Lilly

Eli Lilly

LLY
Rangering i aksjer #15
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals... Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Aksjekurs
$910.55
Markedsverdi
$860.30B
Endring (1 dag)
0.44%
Endring (1 år)
5.28%
Land
US
Handel Eli Lilly (LLY)

Kategori

Inntekter for Eli Lilly (LLY)
Inntekter i Dec 2025 TTM: $65.18B
Ifølge de nyeste økonomiske rapportene til Eli Lilly er selskapets nåværende inntekter (TTM) $65.18B. I 2024 hadde selskapet inntekter på $45.04B en økning sammenlignet med inntektene i 2023, som var $34.12B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Eli Lilly fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $65.18B 0.00%
2025 $65.18B 44.70%
2024 $45.04B 32.00%
2023 $34.12B 19.56%
2022 $28.54B 0.79%
2021 $28.32B 15.40%
2020 $24.54B 9.95%
2019 $22.32B 3.84%
2018 $21.49B 7.61%
2017 $19.97B -5.88%
2016 $21.22B 6.33%
2015 $19.96B 1.75%
2014 $19.62B -15.13%
2013 $23.11B 2.25%
2012 $22.60B -6.93%
2011 $24.29B 5.25%
2010 $23.08B 5.68%
2009 $21.84B 7.19%
2008 $20.37B 9.33%
2007 $18.63B 18.75%
2006 $15.69B 7.14%
2005 $14.65B 5.68%
2004 $13.86B 10.14%
2003 $12.58B 13.59%
2002 $11.08B -4.03%
2001 $11.54B 6.26%
2000 $10.86B 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$58.74B -9.88%
GB
$94.19B 44.51%
US
$61.16B -6.17%
US
$56.15B -13.85%
CH
$65.01B -0.26%
US